ePRO Consortium Announces Open Access Article In collaboration with the DIA Study Endpoints Community, C-Path’s ePRO Consortium is pleased to announce the open
C-Path Receives FDA Grant to Establish Rare Disease Clinical Outcome Assessment Consortium TUCSON, Ariz., March 19, 2020 — The U.S. Food and Drug Administration’s (FDA) Center for Drug Evaluation and Res
C-Path and Lundbeck Announce a Data Sharing Collaboration to Enable Development of Advanced Drug Development Tools in Alzheimer’s Disease TUCSON, Ariz., March 18, 2020 — The Critical Path Institute (C-Path) and H. Lundbeck A/S (Lundbeck) are proud to a
C-Path to Lead Multi-Stakeholder Engagement on FDA’s Proposed Novel Framework to Enhance the Pediatric Medical Device Ecosystem TUCSON, Ariz., March 17, 2020 — The Critical Path Institute (C-Path) today announced it has been awarded a grant to condu
C-Path Appoints Dr. Klaus Romero as Chief Science Officer TUCSON, Ariz., March 12, 2020 — The Critical Path Institute (C-Path) today announced the appointment of Klaus Rome
C-Path Selects Experienced Neuroscientist to Lead Alzheimer’s Consortium TUCSON, Ariz., March 12, 2020 — The Critical Path Institute (C-Path) today announced it has named Sudhir Sivakumar
February 24, 2020 Use of Biomarkers to Improve Immunosuppressive Drug Development and Outcomes in Renal Organ Transplantation: A Meeting Report
ERA4TB, an International Consortium to Accelerate the Development of Comprehensive Treatments Against Tuberculosis C-Path, Ltd. and more than 30 partners from 13 countries participate in the ERA4TB project. The ERA4TB (European Regimen Ac
December 5, 2019 Development of a Disease Progression Model for Leucine-Rich Repeat Kinase 2 in Parkinson’s Disease to Inform Clinical Trial Designs Ahamadi M, Conrado DJ, Macha S, Sinha V, Stone J, Burton J, Nicholas T, Gallagher J, Dexter D, Bani M, Boroojerdi B, Smit...